rofecoxib has been researched along with Akinetic-Rigid Variant of Huntington Disease in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malonic acid (MA) is a reversible inhibitor of succinate dehydrogenase (SDH) which induces mitochondrial dysfunction followed by secondary excitotoxicity and apoptosis due to generation of reactive oxygen species." | 1.39 | Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. ( Kalonia, H; Kumar, A; Mishra, J; Sharma, N, 2013) |
| "Quinolinic acid (QA) is a well-known excitotoxic agent that could induce behavioral, morphological and biochemical alterations similar with symptoms of Huntington's disease (HD), by stimulating NMDA receptors." | 1.35 | Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. ( Kalonia, H; Kumar, A; Kumar, P; Nehru, B, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, A | 2 |
| Sharma, N | 1 |
| Mishra, J | 1 |
| Kalonia, H | 2 |
| Kumar, P | 1 |
| Nehru, B | 1 |
| Norflus, F | 1 |
| Nanje, A | 1 |
| Gutekunst, CA | 1 |
| Shi, G | 1 |
| Cohen, J | 1 |
| Bejarano, M | 1 |
| Fox, J | 1 |
| Ferrante, RJ | 1 |
| Hersch, SM | 1 |
3 other studies available for rofecoxib and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status.
Topics: Animals; Body Weight; Caffeic Acids; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Disease Models, A | 2009 |
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice.
Topics: Acoustic Stimulation; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 2004 |